The Society for Immunotherapy of Cancer has accepted two abstracts in relation to the trial of Alloplex’s lead technology platform, SUPLEXA, for presentation at this year’s 38th annual SITC meeting and conference. The posters to be presented by Dr. Rohit Joshi, alongside the Alloplex leadership team, are: W...
Topic: Scientific News
-
September 7, 2023
Two abstracts on Alloplex’s lead technology platform, SUPLEXA, accepted for presentation at SITC23
Dr. Rohit Joshi of CRSA and Alloplex's leadership team will present the latest developments and data from SUPLEXA-101 phase 1 in-human trials in San Diego, CA (November 1 - 5, 2023)
Read More -
July 25, 2023
Dr. Borriello to present at CHI immuno-oncology summit 2023 in Boston
Dr. Frank Borriello, Alloplex Biotherapeutics Inc’s Founder and CEO, will be speaking at CHI’s 11th Annual Immuno-Ongolocy Summit #IOSummit and chairing the Emerging Cell-Based Therapies session at the Seaport Hotel, Boston, M.A. on August 9. The session starts at 8.55 am and Dr. Borriello’s presentation ‑ enti...
Read More -
June 14, 2023
Alloplex will participate in the CHI’s 7th Annual Immuno-Oncology Summit Europe
Alloplex Biotherapeutics’ Founder and CEO, Dr. Frank Borriello, is a speaker within the Gamma Delta Immunotherapy ‘Exploiting and Enhancing Unique Properties for Cancer Treatment’ track of the CHI Immuno-Oncology Summit Europe, taking place in London from June 20 to 22, 2023. His presentation, entitled ‘SUPLEXA...
Read More